Novo Nordisk reports good interactions with regulators for end of year close of Catalent deal
Novo Nordisk still expects its deal with Catalent to close by the end of 2024 based on interactions with regulators in different geographies, CEO Lars Fruergaard Jørgensen said.Novo Nordisk still expects its...To view the full article, register now.
Already a subscriber? Click here to view full article